Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 163

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 163
---
 agents, or their or his or her substitute
or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as
amended, this Registration Statement on Form F-1 has been signed by the following persons in the capacities and on the date indicated.

| Name and Signature    |     | Title(s)                                                                                  |     | Date |
|                       |     | Chief Executive Officer, Director,                                                        |     |      |
| Stephen Stamp         |     | Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer |     |      |
|                       |     | Non-Executive Chairman of the Board                                                       |     |      |
| Stephen Parker        |     |                                                                                           |     |      |
|                       |     | Senior Independent Non-Executive Director                                                 |     |      |
| Simon Turton, Ph.D.   |     |                                                                                           |     |      |
|                       |     | Non-Executive Director                                                                    |     |      |
| Sijmen de Vries, M.D. |     |                                                                                           |     |      |
|                       |     | Non-Executive Director                                                                    |     |      |
| Ann Merchant          |     |                                                                                           |     |      |

| II-5 |

<div align='center'>AUTHORIZED REPRESENTATIVE</div>

Pursuant to the requirements of the
Securities Act of 1933, as amended, this Registration Statement on Form F-1 has been signed by the undersigned on this
day of
, .

| By:    |                                                |
| Name:  |                                                |
| Title: | Authorized Representative in the United States |

| II-6 |

<div align='center'>Exhibit Index</div>

| Exhibit 
 Number  
 1.1*    
 3.1     
 4.1     |     | Title                                                                                                                                                                                                                                                                                                                                                                                         
 Form of Underwriting Agreement, by and between Biodexa Pharmaceuticals PLC and                .                                                                                                                                                                                                                                                                                               
 Articles of Association of Biodexa Pharmaceuticals PLC, adopted on November 22, 2024 (incorporated by reference to Exhibit 1.1 to the Company’s Report on Form 6-K, filed with the SEC on December 27, 2024).                                                                                                                                                                                 
 Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 2.1 to the Company’s Annual Report on Form 20-F, filed with the SEC on